论文部分内容阅读
Results of a first-in-human, phase Ⅰ/Ⅱ trial of ASP2215, a selective, potent inhibitor of FLT3/Axl i
【作 者】
:
【机 构】
:
Sidney Kimmel Comp Cancer Ctr at Johns Hopkins, Baltimore, MD
【出 处】
:
2015年临床肿瘤学新进展学术研讨会
【发表日期】
:
2015年3期
其他文献
Final overall survival (OS) results of the phase Ⅲ PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis)
会议
Randomized phase Ⅲ trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels
会议
Randomized phase Ⅱ, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (
会议
Final clinical results of a randomized phase Ⅱ international trial of everolimus vs. sunitinib in pa
会议
A randomized phase Ⅱ study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimu
会议
Docetaxel and/or zoledronic acid for hormone-na(i)ve prostate cancer: First overall survival results
会议
Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respo
会议
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or re
会议